study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.

control group (24 patients) did not receive 3-daysCetrorelix Acetate (no intervention). Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.

Cetrotide

no Cetrotide

Total

Sex: Female, Male

Race (NIH/OMB)

Region of Enrollment

Serum E2 levels (Serum E2 level in picograms/ml) were evaluated daily.

Daily Serum E2 Levels

MOD (maximal ovarian diameter in mm) were evaluated daily.

Daily Maximal Ovarian Diameter

-All patients were clinically evaluated for the presence of abdominal pain and if present was graduated using a numerical pain visual analogue scale (VAS) with 0 means no pain and 10 means severe intolerable pain .

study group (24 patients = intervention) received intervention for 3-days Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.

Daily Numerical Pain Visual Analogue Scale Score

Blood samples were obtained under complete aseptic condition for determination of hematocrits value (Ht%)

Daily Hematocrits Value

-US detected severity grades of ascites determined at Day -0, Day -3 and Day -8.

Ultrasound Detected Severity Grades of Ascites From Days 0-8

Daily Total Leucocytic Count

-severity grades of gastrointestinal manifestations determined at Day -0,Day -3 and Day -6.

Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy

study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD(maximal ovarian diameter) were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.

Overall Study

dr khalid M Salama

Infertility

study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.

Cetrorelix

Benha university hospitalا

Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome

Sequential E2 Levels Not Ovarian Maximal Diameter Estimates Were Correlated With Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome

khalid mohammed salama

director clinical research

Benha University

These patients will receive Dextrose 5% and 0.9 NS in their maintenance IV fluids

These patients will receive Dextrose 5% and 0.45 NS in their maintenance IV fluids

Hyponatremia

Use of 0.9 Normal Saline for maintenance IV fluids

0.9 Normal Saline

Use of 0.45 Normal Saline for maintenance IV fluids

0.45 Normal Saline

Ann and Robert H. Lurie Children's Hospital of Chicago

Reexamining Hypotonic Intravenous Fluid Use

Reexamining Hypotonic Intravenous Fluid Use in Pediatric Patients With Gastroenteritis.

Waheeda Samady, MD

Pediatric Hospitalist

Ann & Robert H Lurie Children's Hospital of Chicago

Oral vismodegib, 150mg per day for 12 weeks.

Those to whom the inactive placebo is given.

Vismodegib

The final wound size taken immediately after the completion of Mohs surgery (i.e., upon reaching tumor-free tissue margins) was determined using pre treatment lesion outlined plus one additional concentric 2mm margin removed to establish an objective consistent measure for wound size. The diameter of the final wound size was measured in mm.

Mohs Micrographic Surgery (MMS)

A secondary variable is the complete response rate, defined as the proportion of patients with no histological evidence of basal cell carcinoma on the post treatment MMS excision of the target tumor area. For this analysis, the placebo data will be pooled together to calculate the complete response rate for the placebo group.

Complete Response Rate

Inactive Placebo

Dr. Abel Torres, PI

Basal Cell Carcinoma

Placebo

Vismodegib for Treatment of Basal Cell Carcinoma

Placebo-controlled, Double Blind Study to Assess Efficacy and Safety of Oral Vismodegib for the Treatment of Basal Cell Carcinoma Preceding Excision by Mohs Micrographic Surgery (MMS)

hyponatremia/diarrhea

Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome

Reexamining Hypotonic Intravenous Fluid Use

Vismodegib for Treatment of Basal Cell Carcinoma

Reference Values for Non-invasive Hydration Status Markers H10-14

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus